For example, a combinatorial trial with the CDK4/6 inhibitor abemaciclib and the autophagy inhibitor hydroxychloroquine (NCT04523857) has been designed to eliminate dormant breast cancer cells [73]. Here, CDK4 is linked to breast carcinoma.